Clinical Trial

Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 6, 2026 (before its estimated August 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
Psoriasis is a common immune-mediated inflammatory skin disease affecting at least 100 million individuals worldwide. In Egypt, the prevalence of psoriasis ranges between 0.19% and 3% of the Egyptian people. It is associated with poor quality of life, reduced life expectancy and multimorbidity including psoriatic arthritis, obesity and cardiovascular disease. Vaspin (VASP, SERPIN 12) is a recently discovered adipokine that has been isolated from the visceral adipose tissue of a rat model of type 2 diabetes. It is coded by the gene SERPNA12 located on the long arm of chromosome 14q32.13 and consists of six exons and five introns.
Trial Details
NCT Number NCT07320872
Lead Sponsor Aswan University
Conditions Psoriasis Vulgaris
Enrollment 60 participants
Start Date 2025-08-10
Primary Completion 2026-08-10 (estimated)
Study Completion 2026-08-20 (estimated)
Updated on ClinicalTrials.gov 2026-01-06